JCPenney and Ashley Graham defy the Ozempic trend with a bold, size-inclusive campaign that celebrates curves and drives ...
The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...
Ozempic, MRI machines and flat screen televisions all emerged out of fundamental research decades earlier — the very types of ...
Constellation Brands, Inc. is a growing, high-quality beer business trading at a discount to fair value. Click here to read ...
Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...
Zacks Investment Research on MSN
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...
Semaglutide is a so-called GLP-1 drug: a hormone mimicker meant to treat type 2 diabetes. Our bodies secrete natural GLP-1 hormones after we eat to help start insulin production, which regulates blood ...
LONDON (Reuters) -Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's mass market for weight-loss drugs. The Danish drugmaker ...
13d
Michigan to limit Medicaid coverage for weight loss drugs to people with diabetes, morbid obesity
Michigan lawmakers plan to save money in the state's Medicaid program by limiting the use of popular weight loss drugs to ...
Danish food tech startup Matr Foods has raised €20M ($23M) in Series A funding for its mycelium meat, adding to €20M in debt ...
Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback